Cited by 93Cardiomyopathy and Myosin StudiesCardiac Fibrosis and RemodelingVirus-based gene therapy research

Intramyocardial VEGF-B 167 Gene Delivery Delays the Progression Towards Congestive Failure in Dogs With Pacing-Induced Dilated Cardiomyopathy

Open access
Pepe, Martino, Mamdani, Mohammed, Zentilin, Lorena, Csiszar, Anna, Qanud, Khaled, Zacchigna, Serena, Ungvari, Zoltan, Puligadda, Uday +6 more·2010·Circulation Research

Abstract

Rationale : Vascular endothelial growth factor (VEGF)-B selectively binds VEGF receptor (VEGFR)-1, a receptor that does not mediate angiogenesis, and is emerging as a major cytoprotective factor. Objective : To test the hypothesis that VEGF-B exerts non-angiogenesis-related cardioprotective effects in nonischemic dilated cardiomyopathy. Methods and Results : AAV-9-carried VEGF-B 167 cDNA (10 12 genome copies) was injected into the myocardium of chronically instrumented dogs developing tachypacing-induced dilated cardiomyopathy. After 4 weeks of pacing, green fluorescent protein-transduced dogs (AAV-control, n=8) were in overt congestive heart failure, whereas the VEGF-B-transduced (AAV-VEGF-B, n=8) were still in a well-compensated state, with physiological arterial P o 2 . Left ventricular (LV) end-diastolic pressure in AAV-VEGF-B and AAV-control was, respectively, 15.0±1.5 versus 26.7±1.8 mm Hg and LV regional fractional shortening was 9.4±1.6% versus 3.0±0.6% (all P <0.05). VEGF-B prevented LV wall thinning but did not induce cardiac hypertrophy and did not affect the density of α-smooth muscle actin-positive microvessels, whereas it normalized TUNEL-positive cardiomyocytes and caspase-9 and -3 activation. Consistently, activated Akt, a major negative regulator of apoptosis, was superphysiological in AAV-VEGF-B, whereas the proapoptotic intracellular mediators glycogen synthase kinase (GSK)-3β and FoxO3a (Akt targets) were activated in AAV-control, but not in AAV-VEGF-B. Cardiac VEGFR-1 expression was reduced 4-fold in all paced dogs, suggesting that exogenous VEGF-B 167 exerted a compensatory receptor stimulation. The cytoprotective effects of VEGF-B 167 were further elucidated in cultured rat neonatal cardiomyocytes exposed to 10 −8 mol/L angiotensin II: VEGF-B 167 prevented oxidative stress, loss of mitochondrial membrane potential, and, consequently, apoptosis. Conclusions : We determined a novel, angiogenesis-unrelated cardioprotective effect of VEGF-B 167 in nonischemic dilated cardiomyopathy, which limits apoptotic cell loss and delays the progression toward failure.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circresaha.110.220855

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Successful cardiac transduction in large species requires surgical and catheter-based approaches that preferentially target the heart.

    “Successful cardiac transduction in large species requires surgical and catheter-based approaches that can preferentially target the heart”
  • Canine hearts are typically transduced via methods that specifically target the myocardium such as direct intramyocardial and percutaneous transendocardial injections, which are technically more challenging than simple IP and IV methods.

    “Canine hearts are typically transduced via methods that specifically target the myocardium such as direct intramyocardial (Pepe, et al., 2010) and percutaneous transendocardial injections (Bish, Sleeper, et al., 2008) which are technically more challenging than simple IP and IV methods.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pepe, M., Mamdani, M., Zentilin, L., Csiszar, A., Qanud, K., Zacchigna, S., Ungvari, Z., Puligadda, U., Moimas, S., Xu, X., Edwards, J. G., Hintze, T. H., Giacca, M., & Recchia, F. A.
Affiliations
  • Scuola Superiore Sant'Anna (IT)
  • From the Department of Physiology (M.P., M.M., K.Q., X.X., J.G.E., T.H.H., F.A.R.), New York Medical College, Valhalla, NY; International Centre for Genetic Engineering and Biotechnology (L.Z., S.Z., U.P., S.M., M.G.), Trieste, Italy; Reynolds Oklahoma Center on Aging (A.C., Z.U.), Department of Geriatric Medicine, University of Oklahoma Health Science Center, Oklahoma City; and Sector of Medicine (F.A.R.), Scuola Superiore Sant’Anna, Pisa, Italy.
Venue
Circulation Research
Published
2010-06-25
Volume
106
Issue
12
Pages
1893-1903
ISSN
  • 0009-7330 (ISSN-L)
  • 1524-4571
OpenAlex
W2148120054
Cited by
93
References
45
Citations by year
2025: 2 · 2024: 8 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 7 · 2019: 4 · 2018: 9 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 10 · 2013: 9 · 2012: 10
FWCI
6.37
Type
journal article
Language
en
Open access
Locations
  • Circulation Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
Funders
National Heart, Lung, and Blood Institute (P01HL043023, P01-HL74237, P01HL074237, P01 HL 43023)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
VEGF-B, VEGF receptor 1, dilated cardiomyopathy, tachycardia-induced cardiomyopathy, congestive heart failure, cardiomyocyte apoptosis, Akt signaling, GSK3β, FOXO3, angiotensin II, oxidative stress, cardioprotection, AAV gene delivery
MeSH terms
Adenoviridae, Animals, Cells, Cultured, Disease Models, Animal, Dogs, Heart Failure, Male, Cardiomyopathies, Myocardium, Gene Transfer Techniques, DNA, Complementary, Oxidative Stress, Disease Progression, Myocytes, Cardiac, Neuropilin-1, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review